

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Session date	Session Start	Session End	Room Name	Session Group / Title / Learning objectives	Presentation Start	Presentation Title
Wednesday, 2 June 2021	14:15:00	15:00:00	Room 1	What is New (WIN) What is new in axial spondyloarthritis? To learn most recent data on diagnosis, classification, outcome assessment, and treatment of axial spondyloarthritis (including radiographic and non-radiographic forms).	14:15:00	Introduction
				14:20:00	Non-radiographic or radiographic axial SpA – does it matter?	
				14:50:00	Q&A	
	15:45:00		Room 10	EULAR Projects What the rheumatologist needs to know to interpret studies in 2021 Methodology of clinical trials and observational studies has changed over time. The phenotype of patients that are studied has also changed over time. In this session, methodological aspects of study design and data analysis will be discussed. Topics like selection bias, propensity scores and ROC-curve analysis will be discussed.	14:15:00	Introduction
				14:20:00	Patient profiles in the era of biological treatments - Implications for trial design and interpretation	
				14:45:00	How to improve your propensity score models?	
					15:10:00	Measurements, composite scores and the art of 'cutting-off'
					15:35:00	Abstract to be included
			Room 11	Joint, PARE Help! What do I need to cope with my RMD? To present what people with inflammatory diseases should know about managing their disease. To give an overview of various digital solutions for monitoring and coping strategies.	14:15:00	Introduction
					14:20:00	What my newly diagnosed patient should know about the disease, its risk factors and comorbidities
					14:35:00	Foot problems and foot healthcare
					14:50:00	The influence of physical activity and sports on inflammation
15:05:00					Gaining user-generated evidence - Which mobile health application fits best to monitor and support?	
				15:20:00	Debate	
		Room 12	Practical skills New assessments in clinical practice (blank)	14:15:00	How to assess heart function in Rheumatic diseases?	
				14:35:00	Value of Patient reported outcome measures in Rheumatic Diseases	
				14:55:00	BASDAI and ASDAS: should we use both, or one should be preferred?	
				15:15:00	Is there an added value of imaging to the Composite index measurement of disease activity in patients with Rheumatoid Arthritis?	
				15:35:00	Q&A	
		Room 13	Practical skills Meet the EULAR Editors Obtain answers to pertinent issues related to paper submissions and EULAR journal processes; Develop skills of self-judgement regarding suitability of manuscripts for the EULAR journals.	14:15:00	Introduction	
				14:20:00	Issues related to RMD	
				14:30:00	Issues related to ARD	
				14:40:00	Publication ethics and scientific conduct	
				14:50:00	Group discussion	
		Room 3	Clinical Science Treating SLE to target: remission or low disease activity? Remission is the target of treatment in SLE. However a complete remission might be a difficult target to reach. In this session the steps toward a common definition of remission in SLE will be described as well as the characteristics of the Lupus Low disease Activity State.	14:15:00	Introduction	
				14:20:00	Toward a common definition of remission: the DORIS project	
				14:40:00	The Lupus Low Disease Activity State	
				15:00:00	Physician global assessment in the definition of targets in SLE management: yes or no?	
				15:20:00	Is remission achievement possible with the today's drugs?	
				15:40:00	Q&A	
		Room 4	From Bench to Bedside New perspectives on therapeutic immune tolerance To understand how tolerogenic strategies may lead to paradigm shifts in autoimmunity.	14:15:00	Introduction	
				14:20:00	The potential of costimulation blockade	

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Wednesday, 2 June 2021 14:15:00	15:45:00	Room 8	<p>The Young Rheumatologist Implementation of immunological knowledge in rheumatology research and practice To identify the role of general and more deep understanding and knowledge of immunology in the practice of rheumatologists. To get clinical examples of how the knowledge of immunology could be implemented. To highlight the learning opportunities in immunology for rheumatologists and to describe a path of translational research scientist.</p>	<p>14:15:00 Introduction 14:20:00 It's never lupus'! (From TV show Dr. House) 14:35:00 Q&A 14:40:00 From the clinic to translational research 14:55:00 Q&A 15:00:00 Gathering knowledge and experience in immunology as rheumatologist 15:15:00 Q&A 15:20:00 Immuno-oncology for rheumatologists: not just checkpoint inhibitors 15:35:00 Q&A</p>
		Room 9	<p>Health Professionals in Rheumatology (HPR) HPR Welcome session: The value of Diversity Delegates will: be aware of top publications of HPR since last EULAR; know how to navigate the congress in order not to miss any interesting presentation or networking event; have knowledge on main challenges that HPR are facing currently and their solutions in current practice; have seen examples on good multidisciplinary clinical teamwork, from different centres in Europe and beyond.</p>	<p>14:15:00 Introduction 14:20:00 Appetizer: TOP year news from HPR 14:35:00 Q&A 14:40:00 Entree: Making the best use of the EULAR Congress 14:55:00 Q&A 15:00:00 Main: The challenges and the opportunities of HPR nowadays; how can we shape the world? 15:15:00 Q&A 15:20:00 Dessert: Brilliant examples of multidisciplinary teamwork in rheumatology 15:35:00 Q&A</p>
15:00:00	15:45:00	Room 1	<p>How to Treat (HOT) How to treat spondyloarthritis To provide an update on the newest evolutions in management of spondyloarthritis in gut and joint</p>	<p>15:00:00 Introduction 15:05:00 Strategies towards early and longterm remission in spondyloarthritis and beyond the joint 15:35:00 Q&A</p>
16:15:00	17:45:00	Room 11	<p>PARE Challenges for Patients and Patients' Organisations in Times of the Pandemic To give an overview of organisations' activities for people with RMDs. To outline challenges organisations have faced and how they have tried to overcome these. To give an update on Sars-Cov2 research.</p>	<p>16:15:00 Supporting patients: information, helpline, coping support, shielding support [UK experience] 16:30:00 Q&A 16:35:00 Supporting patients: information, helpline, coping support, shielding support (German experience) 16:50:00 Q&A 16:55:00 Economic challenges for patient organisations and how to overcome them 17:10:00 Q&A 17:15:00 Coronavirus research + discussion 17:30:00 Q&A 17:35:00 Abstract to be included</p>

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Wednesday, 2 June 2021	16:15:00	17:45:00	Room 9	Health Professionals in Rheumatology (HPR), EULAR Projects Like a gearwheel: HPR's research, education, and practice Delegates will be able to: discuss the process and outputs of research supported by EULAR HPR grants; recognise different projects managed by the HPR School of Rheumatology; discuss the importance of quality of care and difficulties of harmonising its measurement; describe the key steps of the implementation process and relate these to service improvement.	16:15:00	Introduction				
					16:20:00	HPR Research: Overview of the EULAR (and other) grants and future directions				
					16:28:00	HPR Education: Activities in course to reduce disparities across countries				
					16:36:00	HPR Quality of care: should we aim for a common audit in Europe?				
					16:44:00	Building all up: Key steps on implementation science				
					16:52:00	Abstract to be included				
					17:02:00	Q&A				
Wednesday, 2 June 2021	18:15:00	19:45:00	Room 7	Basic and Translational Science New toys in rheumatology: single cell RNA and epigenetic sequencing, the holy grail? Learning the power of single cell analyses to improve our knowledge of rheumatic diseases, and patient stratification; Learning the latest development in single cell transcriptome and epigenome analyses from experts in the field.	18:15:00	Introduction				
					18:20:00	Single cell analyses to identify predictive signatures of rheumatoid arthritis flares (PMID 32668112)				
					18:35:00	Single cell analyses: deciphering tissue biology in health and disease across time and space				
					18:50:00	X chromosome inactivation and SLE pathogenesis: gender and epigenetics				
					19:05:00	Detecting T cells involved in immune responses through single repertoires snapshots				
					19:20:00	Abstract to be included				
					19:30:00	Abstract to be included				
					19:40:00	Q&A				
									18:15:00	Introduction
									18:20:00	Mapping: Efficacious interventions and required competences to provide remote care in rheumatology
				18:35:00	The Basics still work: Telephone help lines					
				18:42:00	Future today: Innovative models for physical care delivery					
				18:49:00	The essentials: Providing first mental aid - from identification to referral					
				18:56:00	Debate					
Thursday, 3 June 2021	08:15:00	09:45:00	Room 7	Basic and Translational Science Immunodeficiency and autoimmune disease To appreciate the association of primary immunodeficiency with autoimmunity; To enhance the understanding of monogenic / polygenic immune defects in the development of autoimmune diseases; To dissect the role of the different immune cell network in the development of autoimmune diseases in patients with known primary immunodeficiency; and to heighten the awareness of rheumatologists of disease / drug induced immunosuppressed state	08:15:00	Introduction				
					08:20:00	Autoimmunity and primary immunodeficiency				
					08:40:00	Genetic basis of primary immunodeficiency syndromes: implications in autoimmunity				
					09:00:00	Self-tolerance, immunodeficiency and autoimmunity				
					09:20:00	Secondary immunodeficiency in patients with autoimmune disease				

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Date	Time	Room	Topic	Start	End	Content
Thursday, 3 June 2021	10:15:00	Room 1	What is New (WIN) Fatigue in Arthritis, SpA & systemic rheumatic diseases Understand the impact of fatigue on patients with chronic inflammatory rheumatic conditions; Appreciate pharmacological and non-pharmacological management strategies of fatigue in these patients.	10:15:00	10:20:00	Introduction
				10:50:00	10:50:00	Fatigue in Arthritis, SpA & systemic rheumatic diseases Q&A
	11:45:00	Room 11	PARE Challenges for working people with RMDs in pandemic times To address the impact on working conditions and safety; To outline how legal measures support to stay at work, enable better social protection and prevent work disability (align with other chronic conditions); To highlight the importance of disease prevention and health promotion in the working environment.	10:15:00	10:20:00	Introduction
				10:35:00	10:50:00	Impact of the pandemic on working conditions of people with RMDs – Results of European surveys A patient organisations' actions to support employees with an RMD Empowered2work: healthy workplaces at home
				11:05:00	11:20:00	EU OSHA Campaign on healthy work-places focuses on musculoskeletal disorders Abstract to be included
				11:30:00	11:30:00	Q&A
11:00:00	11:45:00	Room 1	How to Treat (HOT) Treatment of severe lupus nephritis Understand the prevalence and definition of severe lupus nephritis; Appreciate the clinical diagnosis, followup and monitoring of patients with severe lupus nephritis;	11:00:00	11:05:00	Introduction
				11:35:00	11:35:00	Treatment of severe lupus nephritis Q&A
13:30:00	14:15:00	Room 1	What is New (WIN) WIN Giant Cell Arteritis To understand current concepts in diagnosis, therapy and long-term management of patients with giant cell arteritis.	13:30:00	13:35:00	Introduction
				14:05:00	14:05:00	WIN: GCA Q&A
15:00:00		Room 10	EULAR Projects Standing Committee on Clinical Affairs To learn, how development of new and updated EULAR recommendations is being performed To learn, how difficult-to-treat rheumatic diseases are being treated in an evidence-based manner To learn, how the various aspects of rheumatic diseases are handled in an evidence-based manner	13:30:00	13:45:00	Points to Consider on the Assessment of Competences in Rheumatology Training
				14:00:00	14:15:00	Definition and recommendations for the management of difficult to treat rheumatoid arthritis Points to Consider on Therapeutic Drug Monitoring in inflammatory arthritis Development And Validation of a disease activity score in adult onset Still's Disease: the "DAVID" project
				14:30:00	14:45:00	Points to Consider for Conducting Clinical Trials in Individuals at risk of Rheumatoid Arthritis Recommendations for cardiovascular risk management in Rheumatic and Musculoskeletal Diseases (including SLE and the antiphospholipid syndrome)

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

<p>Thursday, 3 June 2021 13:30:00</p>	<p>15:00:00</p>	<p>Room 11 PARE Improving collaborative research and patients' participation in health decision-making To provide best practices examples of collaborative research and PPI, evidencing EULARs leading role and opportunities for PPI. To highlight the added value of patients' participation in health decision-making.</p>	<p>13:30:00</p> <p>13:35:00</p> <p>13:50:00</p> <p>14:05:00</p> <p>14:20:00</p> <p>14:35:00</p> <p>14:45:00</p>	<p>Introduction</p> <p>Collaborative research: is it really evolving? The EULAR roadmap of Patient Research Partners: how far did we go?</p> <p>Examples of patient involvement and engagement in research</p> <p>From trainee to expert: An engaged route for involvement</p> <p>RheumaMap – Prioritizing patients' unmet needs</p> <p>Abstract to be included</p> <p>Discussion</p>
		<p>Room 12 Practical skills Ultrasound basic in theory To be made aware of ultrasound pitfalls that may influence the scoring of arthritis in the hand; to be introduced to ultrasound examination of the collateral ligaments of the fingers and how they may be affected in inflammatory and degenerative arthritis; to be made aware of how different ultrasound approaches to the arthritic ankle may provide information on ankle involvement of the ankle; to be introduced to the newly developed consensus-based ultrasound scoring system for monitoring crystal depositions in gout.</p>	<p>13:30:00</p> <p>13:50:00</p> <p>13:53:00</p> <p>14:13:00</p> <p>14:16:00</p> <p>14:36:00</p> <p>14:38:00</p> <p>14:58:00</p>	<p>An overview of pitfalls in assessing synovitis and tenosynovitis of the hand + quiz</p> <p>Q&A</p> <p>The involvement of collateral ligaments of the hand in arthritis + quiz</p> <p>Q&A</p> <p>The clinical relevance of the medial and lateral ankle involvement in arthritis + quiz</p> <p>Q&A</p> <p>The development and validation of the OMERACT scoring system for crystal depositions in gout + quiz</p> <p>Q&A</p>
		<p>Room 13 Practical skills Problem solving: How to deal with Glucocorticoids in practice? (blank)</p>	<p>13:30:00</p> <p>13:40:00</p> <p>14:00:00</p> <p>14:10:00</p> <p>14:30:00</p> <p>14:40:00</p>	<p>Presentation of an exemplary difficult case: Glucocorticoids, rheumatic diseases and bone</p> <p>Guided interactive discussion and problem solving</p> <p>Presentation of an exemplary difficult case: Glucocorticoids in vasculitis</p> <p>Guided interactive discussion and problem solving</p> <p>Presentation of an exemplary difficult case: Glucocorticoids in rheumatoid arthritis</p> <p>Guided interactive discussion and problem solving</p>
		<p>Room 2 Clinical Science Oncorheumatology: the crossroads of cancer and musculoskeletal diseases To learn possible associations between rheumatology and oncology; To understand the development of malignancies in inflammatory RMDs; To determine the possible carcinogenicity of antirheumatic drugs; To understand the development and management of immune-related adverse events due to immune-checkpoint inhibition.</p>	<p>13:30:00</p> <p>13:34:00</p> <p>13:48:00</p> <p>14:02:00</p> <p>14:16:00</p> <p>14:30:00</p> <p>14:40:00</p> <p>14:50:00</p>	<p>Introduction</p> <p>Eight pillars of oncorheumatology</p> <p>The winding road from inflammation to cancer</p> <p>Possible carcinogenicity associated with antirheumatic therapies</p> <p>Immune-related adverse events of immune-checkpoint inhibitors: the EULAR points to consider</p> <p>Discussion</p> <p>Abstract to be included</p> <p>Abstract to be included</p>

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

<p>Thursday, 3 June 2021 13:30:00</p> <p>15:00:00</p>	<p>Room 3</p> <p>Clinical Science</p> <p>Shedding new light on Fibromyalgia: is it a matter of Hard or Software?</p> <p>To understand the neurobiological features and abnormalities of fibromyalgia. To explore the relationship between the psycho-social and the neurobiological features of fibromyalgia. To critically appraise the impact of psychotherapy in fibromyalgia and how this relates to the biological underpinnings. To apply all these concepts to clinical practice.</p>	<p>13:30:00</p> <p>13:35:00</p> <p>13:48:00</p> <p>14:01:00</p> <p>14:14:00</p> <p>14:27:00</p> <p>14:37:00</p> <p>14:47:00</p>	<p>Introduction</p> <p>Hardware: The neurobiological signature(s) of Fibromyalgia Software: An integrative model of the neuro-psycho-social features of Fibromyalgia Rewiring in Fibromyalgia: soothing the threats How all this applies to clinical care in rheumatology Abstract to be included Abstract to be included Abstract to be included</p>
	<p>Room 4</p> <p>From Bench to Bedside</p> <p>Stem cells – bridging the understanding of the pathogenesis and treatment of rheumatic diseases</p> <p>To understand the roles and applications of stem cells in immunological disease; To study the role of stem cells in the pathogenesis of rheumatoid arthritis; To appreciate the therapeutic applications of stem cells in degenerative rheumatic diseases.</p>	<p>13:30:00</p> <p>13:35:00</p> <p>13:55:00</p> <p>14:15:00</p> <p>14:35:00</p> <p>14:55:00</p>	<p>Introduction</p> <p>Stem cells in immunological disease: Focus on mesenchymal stem cells Stem cells in immunological disease: Focus on expanded potential stem cells PRIME cells in rheumatoid arthritis Stem cell therapy for degenerative arthritis Q&A</p>
	<p>Room 5</p> <p>Challenges in Clinical Practice</p> <p>Identifying new genetic inflammatory diseases: the example of DADA2 and type I interferonopathies</p> <p>To provide information about genetics and pathophysiology of DADA2 and to highlight its main diagnostic clues and the optimal therapy. To present an overview of the group of type I interferopathies and to illustrate their typical clinical and laboratory manifestations and the new therapeutic advances.</p>	<p>13:30:00</p> <p>13:35:00</p> <p>13:45:00</p> <p>14:05:00</p> <p>14:15:00</p> <p>14:35:00</p>	<p>Introduction</p> <p>The diagnostic challenge of DADA2 Discussion: The diagnostic challenge of DADA2 The emerging spectrum of interferonopathies Discussion: The emerging spectrum of interferonopathies Q&A</p>
	<p>Room 6</p> <p>EULAR Debate</p> <p>Is ethics in clinical management and research of Covid19 patients adequately addressed?</p> <p>Raising the likely therapeutic irregularities committed with these patients. Has non-Covid research suffered from the shift in resources to Covid-research? The balanced social perspective.</p>	<p>13:30:00</p> <p>13:35:00</p> <p>13:45:00</p> <p>13:55:00</p>	<p>Introduction</p> <p>Desperate medicine in Covid-19? Forced diversion to the Covid-19 investigation Q&A and debate</p>
	<p>Room 7</p> <p>Basic and Translational Science</p> <p>Mechanobiology and joint disease: balancing between health and disease?</p> <p>To understand the relation between mechanical stress in musculoskeletal system in health and disease and implications thereof to rheumatic disease</p>	<p>13:30:00</p> <p>13:35:00</p> <p>13:55:00</p> <p>14:15:00</p> <p>14:35:00</p> <p>14:55:00</p>	<p>Introduction</p> <p>Tenocytes: gatekeepers of tendon homeostasis Mechanoinflammation and osteoarthritis Mechanostress in tendons: gateway to rheumatic disease? Tendinopathy: from pathophysiology to treatment Q&A</p>

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Day	Time	Room	Topic	Start	End	Content
Thursday, 3 June 2021	13:30:00	Room 8	The Young Rheumatologist Biobanking in Rheumatology			
			The multi-omics technologies are becoming every day more economically sustainable and widespread in rheumatology research aiming to a better understanding of disease pathogenesis and the identification of predictors of response and novel therapeutic targets. Side by side with the rise of the systems approach to rheumatic diseases, the availability of high-quality, harmonized biological samples coming from the disease affected sites paired with curated clinical information is becoming the bottleneck in biomedical research. The young rheumatologist, particularly if working in small peripheral centres, is likely to be frightened away by the complexity of data acquisition and analysis required by with "omics" technologies. However, the establishment of a diffuse network of biobanks can be instrumental for the research in rheumatology. The participation of young rheumatology to larger international consortiums is instrumental for both research progress and personal career development.			
			Learning objectives: To provide insights on the ethical, logistic and legal aspects associated with human tissue biobanking; To review some of the successful experiences and examples of the possibilities offered by biobanking of the most affected tissues in rheumatic diseases; To get informed about the current and future opportunities offered by international consortium aiming to			
				13:30:00	Introduction	
				13:35:00	Biobank & registries: ethics and law	
				13:50:00	Patients perspective and public engagement	
				14:05:00	Q&A	
				14:10:00	Genomic sampling	
				14:25:00	Beyond the blood: biological samples in rheumatology research	
				14:40:00	International consortia and the young rheumatologist: challenges and opportunities	
		14:55:00	Q&A			
		Room 9	Joint Joint Session EULAR ESCMI and EANM (European Association of Nuclear Medicine) – State-of-the-art nuclear imaging in RMDs To learn about the most recent advances in nuclear imaging applicable to RMDs			
				13:30:00	Introduction	
				13:35:00	Where is the fire: immunoscintigraphy of TNF-driven inflammation in rheumatoid arthritis	
				13:55:00	Beyond FDG: novel PET tracers for macrophage imaging in rheumatoid arthritis	
				14:15:00	SPECT versus PET: pick the right tool for the right job!	
				14:35:00	Abstract to be included	
		14:45:00	Abstract to be included			
14:15:00	15:00:00	Room 1	How to Treat (HOT) Systemic sclerosis and lung involvement: diagnostic work-up and new treatment modalities			
			To understand the minimally required work-up of SSc patients with suspected lung involvement. - To learn how to optimise treatment strategies for SSc-related lung disease			
				14:15:00	Introduction	
				14:20:00	Systemic sclerosis and lung involvement: diagnostic work-up and new treatment modalities	
		14:50:00	Q&A			
15:30:00	16:15:00	Room 1	What is New (WIN) SARS-CoV-2 related Multisystem Inflammatory Syndrome in Children To describe the features and pathophysiology of the paediatric multisystem Kawasaki-like inflammatory syndrome related to SARS-CoV-2 infection.			
				15:30:00	Introduction	
				15:35:00	SARS-CoV-2 related Multisystem Inflammatory Syndrome in Children	
				16:05:00	Q&A	
17:00:00		Room 10	EULAR Projects EULAR Projects in Education and Training			
			To inform the audience about current EULAR activities in Education and Training			
				15:30:00	Introduction	
				15:35:00	The EULAR School of Rheumatology: Introducing a new era in rheumatology education	
				15:55:00	New avenues in education: Mixing the formats	
		16:15:00	EULAR activities in patient education			
		16:35:00	How to navigate yourself in EULAR School Platform			

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

<p>Thursday, 3 June 2021 15:30:00</p> <p>17:00:00</p>	<p>Room 11 Joint, PARE Fertility and family planning with an RMD: a blessing, but also a risk? To provide latest data and facts about fertility and pregnancy in people with RMDs. To share best practices to support (future) parents with an RMD.</p>	<p>15:30:00 Introduction</p> <p>15:34:00 Patient: Fertility and family planning with an RMD: a blessing, but also a risk? 15:42:00 Patient: Fertility and family planning with an RMD: a blessing, but also a risk? 15:50:00 Rheumatologist: Fertility and family planning with an RMD: a blessing, but also a risk? 16:00:00 HPR: Fertility and family planning with an RMD: a blessing, but also a risk? 16:10:00 EMEUNET: Fertility and family planning with an RMD: a blessing, but also a risk?</p> <p>16:20:00 Discussion 16:45:00 Take home messages, session summary and closing</p>
	<p>Room 12 Practical skills Problem solving: Therapeutically refractory myositis Learn about different clinical features of myositis; Learn about approaches in patients with refractory myositis; Learn how to perform a muscle biopsy.</p>	<p>15:30:00 Introduction</p> <p>15:35:00 Demo 1: Case presentation - Refractory muscle weakness 15:50:00 Group discussion 15:55:00 Demo 2: How to perform a muscle biopsy 16:10:00 Group discussion 16:15:00 Demo 3: Case presentation - Myositis with difficult to treat interstitial lung disease 16:30:00 Group discussion 16:35:00 Demo 4: Case presentation - Myositis with refractory skin rash 16:50:00 Group discussion</p>
	<p>Room 13 Practical skills MRI in theory To learn how to best use MRI in osteoarthritis, suspected axial spondyloarthritis, challenging shoulder cases and in early inflammatory arthralgia and arthritides.</p>	<p>15:30:00 Recent advances in MRI in osteoarthritis</p> <p>15:50:00 Differential diagnoses in suspected axial SpA 16:10:00 MRI of the shoulder and its challenges: Arthritis or overuse? 16:30:00 The earliest MRI findings in inflammatory arthralgia and arthritides – How to recognize them and their prognostic importance 16:50:00 Q&A</p>
	<p>Room 2 Clinical Science Comorbidities in gout and hyperuricaemia Review the evidence linking high uric acid to different comorbidities: cardiovascular, renal, other; Assess the current evidence linking different XO1 (xanthine-oxidase inhibition) and cardiovascular risk; Review the potential use of colchicine in cardiovascular risk; Discuss the potential pathogenic effect of high urate levels on the progression of CKD; Review current evidence on the use of U1 T to prevent CKD progression.</p>	<p>15:30:00 Introduction</p> <p>15:35:00 Comorbidities and hyperuricaemia – causality or association? 15:55:00 Gout therapies and cardiovascular risk 16:15:00 Hyperuricaemia and gout in chronic kidney disease 16:35:00 Abstract to be included 16:45:00 Abstract to be included 16:55:00 Q&A</p>
	<p>Room 3 Clinical Science Lyme disease: Myths and reality Learn about Lyme pathogenesis How to recognize Lyme symptoms How to make the diagnosis of Lyme disease</p>	<p>15:30:00 Introduction</p> <p>15:35:00 Persisting complaints after treatment for Lyme borreliosis 16:00:00 Biological diagnosis of Lyme borreliosis, methods and interpretation 16:25:00 Lyme arthritis, persisting infection or auto-immune disease? 16:50:00 Abstract to be included</p>

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

<p>Thursday, 3 June 2021 15:30:00</p>	<p>17:00:00</p>	<p>Room 4</p> <p>From Bench to Bedside Immune events with check point inhibitors To understand what immune processes are taking place during therapy with check-point inhibitors and why are specific autoimmune diseases triggered and not others.</p>	<p>15:30:00</p> <p>15:35:00</p> <p>15:55:00</p> <p>16:15:00</p> <p>16:35:00</p> <p>16:45:00</p> <p>16:55:00</p>	<p>Introduction</p> <p>What are the mechanistic markers for the onset of immune-related adverse events of checkpoint inhibitors? Which are the most common immune-related adverse events of checkpoint inhibitors? Toxicities from immunotherapy: From clinical trials to real-world clinical practice Abstract to be included Abstract to be included Q&A</p>
		<p>Room 5</p> <p>Challenges in Clinical Practice Vaccinations for the immunosuppressed Rheumatological Patients To get day to day guidelines in the prevention of infections in patients on immunosuppressive drugs.</p>	<p>15:30:00</p> <p>15:35:00</p> <p>15:45:00</p> <p>16:05:00</p> <p>16:15:00</p> <p>16:35:00</p>	<p>Introduction</p> <p>Case 1: How to adjust immunosuppressive treatment in RA patients who have planned surgery Discussion: How to adjust immunosuppressive treatment in RA patients who have planned surgery Case 2: Which vaccinations are needed for RA patients on the respective therapies both in normal life and in a situation that they want to visit the jungle Discussion: Which vaccinations are needed for RA patients on the respective therapies both in normal life and in a situation that they want to visit the jungle Q&A</p>
		<p>Room 6</p> <p>Clinical Science The aftermath of metabolic imbalance in OA The association between metabolic stress and OA is complex and highly intricated. Recent perspectives on the relationship between OA symptoms and metabolic syndrome, as well as the role of joint fat tissue in the disease will be discussed. Chronic, low-grade, both articular and systemic inflammation as a therapeutic target.</p>	<p>15:30:00</p> <p>15:35:00</p> <p>15:55:00</p> <p>16:15:00</p> <p>16:35:00</p> <p>16:45:00</p> <p>16:55:00</p>	<p>Introduction</p> <p>Metabolic Syndrome and Osteoarthritis Pain: Common Molecular Mechanisms and Potential Therapeutic Implications The role of joint fat tissue in OA Chronic, low-grade, articular and systemic inflammation as a therapeutic target in OA Abstract to be included Abstract to be included Q&A</p>
		<p>Room 7</p> <p>Basic and Translational Science From bedside to bench – unexpected results of clinical studies that changed our understanding of the disease To learn how some unexpected results of clinical studies changed our understanding of the disease pathophysiology (or optimal outcome measures in clinical trials) and stimulated clinical and basic research.</p>	<p>15:30:00</p> <p>15:35:00</p> <p>16:00:00</p> <p>16:25:00</p>	<p>Introduction</p> <p>From bedside to bench in RA From bedside to bench in SpA From bedside to bench in SLE</p>
		<p>Room 8</p> <p>Practical skills Raising the performance of your presentations As a result of participating, attendees will be better able to: Analyse and describe what makes a presentation great; Choose and create good supporting media; Evaluate your own presentations and learn from others; Access further resources.</p>	<p>15:30:00</p> <p>15:32:00</p> <p>15:34:00</p>	<p>Raising our Performance in presentations</p> <p>Text and tables to figures Q&A</p>

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Thursday, 3 June 2021	15:30:00	17:00:00	Room 9	Health Professionals in Rheumatology (HPR)	15:30:00	Introduction
				Monitoring and restoring health: Should we have a core set for multidisciplinary care in rheumatology		
				Delegates will be able to: gain a better understanding of what a core set is; have increased knowledge of existing core sets developed for multidisciplinary settings; discuss pro and cons of an international core set for multidisciplinary care in RMDs.		
16:15:00	17:00:00	Room 1	How to Treat (HOT)	16:15:00	Introduction	
			Cytokine storm syndromes			
			To understand the rationale for immunomodulatory therapy in cytokine storm syndromes			
			To gain information on the use of anti-cytokine agents in cytokine storm syndromes associated with rheumatic diseases			
			To discuss the role of anti-rheumatic medications in the management of COVID-19-related cytokine storm syndrome			
17:15:00	18:45:00	Room 7	Basic and Translational Science	17:15:00	Introduction	
			Emerging molecular targets in OA			
			Molecular pathogenesis of OA is a rapidly evolving area. Considerable insight has come from preclinical models which are concordant with outcomes of human trials. New preclinical targets are emerging and bring with them a completely new way to view future therapeutic targeting in OA.			
Friday, 4 June 2021	08:15:00	09:45:00	Room 7	Basic and Translational Science	08:15:00	Introduction
				Origin and role of myeloid cells during homeostasis and inflammation		
				Understand origin and role of macrophages and neutrophils.		
10:15:00	11:00:00	Room 1	What is New (WIN)	10:15:00	Introduction	
			Imaging in the assessment of connective tissue diseases			
			Imaging techniques are becoming very important in the assessment of patients with CTDs. In the present section the most recent advances on the use of imaging in the assessment of rare and complex disease will be discussed.			
11:00:00	11:45:00	Room 1	How to Treat (HOT)	11:00:00	Introduction	
			Hydroxychloroquine: a multifaceted drug			
			Antimalarial drugs are widely used in RMDs. The aim of this session is to review the mechanism of action of hydroxychloroquine, to discuss its use in RMDs as well as in other non rheumatic conditions. The story of HCQ and COVID19 will be also reviewed.			

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Friday, 4 June 2021 13:30:00	14:15:00	Room 1 What is New (WIN) What is new in Psoriatic Arthritis? To learn about the clinical practice outcome assessment as oppose to the ones issues in clinical trials. Benefits and disadvantages of the new and old clinical assessments.	13:30:00 13:35:00 14:05:00	Introduction "To Lump or to split? – PsA outcome assessment in clinical practice and trials" Q&A
	15:00:00	Room 10 EULAR Projects EULAR Projects in Paediatric Rheumatology To present the current and future research projects of PReS in collaboration with other research networks. To provide an overview of the ongoing activities of EMERGE and Working Parties.	13:30:00 13:35:00 13:52:00 14:09:00 14:26:00 14:43:00	Introduction Collaborative projects between CARRA and PReS The growing activities of EMERGE Opportunities and challenges of participation in the ERN The collaboration between PRINTo and PReS Report of the progresses of PReS Working Parties
		Room 11 Joint, PARE Myths and taboos around relationships: strategies for a sexy life To address self-esteem and disease related issues in sexual life of (young) people with RMDs. To highlight reproductive health issues as one of the major concerns for young people with RMDs.	13:30:00 13:35:00 13:50:00 13:55:00 14:10:00 14:15:00 14:30:00 14:35:00 14:45:00	Introduction The impact of an RMD on interpersonal relationships Q&A My partner has an RMD Q&A How to communicate about intimacy with my patients Q&A Abstract to be included Abstract to be included
		Room 12 Practical skills CAPILLAROSCOPY Learners will be instructed to use a fast track algorithm in order to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". In addition, learners will appreciate the Very early nailfold capillaroscopic nonspecific abnormalities that may predict the progression to the scleroderma pattern. Learners will be informed about the most important risk factors that may induce the endothelial damage that start the Raynaud's phenomenon. The most common capillaroscopic patterns will be explained and instructed on how to be quantified, in addition the different tools available for the analysis will be described. The predictive and prognostic role of capillaroscopy in systemic sclerosis will be explained and documented. Learners at the end of the session will have understood when a capillaroscopic pattern is pathologic and what to do. Learners will observe on live patients how the nailfold capillaroscopic analysis is done and will discuss with the tutors the diagnosis.	13:30:00 13:35:00 13:45:00 13:50:00 14:00:00 14:05:00 14:10:00 14:20:00 14:25:00 14:30:00 14:40:00 14:45:00 14:50:00	Introduction and State of Art 2021 A fast track algorithm to differentiate a 'scleroderma pattern' from a 'non-scleroderma pattern' Demo 1: Optimised use of the nailfold capillaroscope (with patient and videocapillaroscope) 2021 update on methods and tools for quantization of the capillaroscopic morphological changes Demo 2: Clinical Case 1 Group discussion (Q&A) Reliability of capillaroscopic characteristics versus instrumental detection Demo 3: Clinical Case 2 Group discussion (Q&A) Very early nailfold capillaroscopic nonspecific abnormalities may predict the progression to the scleroderma pattern and early disease Demo 4: Clinical Case 3 Group discussion (Q&A) BURNING QUESTIONS AND CONCLUSIONS
		Room 13 Practical skills I want to see that poster!		

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Friday, 4 June 2021 13:30:00	15:00:00	Room 13	As a result of participating, attendees will be better able to: Analyse and describe what makes a poster great; Choose and create good supporting media; Evaluate your own posters and learn from others; Access further resources.	13:30:00	Making posters a learning experience
				13:32:00 13:34:00	Helping passers-by catch your message right Q&A
		Room 2	Clinical Science Difficult to treat RA: definitions and mechanisms To understand the concept "difficult to treat rheumatoid arthritis". To gain insight into selected factors contributing to difficult to treat RA.	13:30:00	Introduction
				13:35:00 13:55:00 14:15:00 14:35:00 14:45:00 14:55:00	Difficult to treat RA: definitions and epidemiology What can the synovial tissue learn us about difficult to treat RA The role of comorbidities in difficult to treat RA Abstract to be included Abstract to be included Q&A
		Room 3	Clinical Science Quantitative imaging To get insight into recent advances in quantitative imaging and learn how novel approaches to assessing imaging can support therapy monitoring and clinical decision making in rheumatology.	13:30:00	Introduction
				13:35:00 14:00:00 14:25:00 14:50:00	Can quantitative PET imaging contribute to tailored therapy in rheumatology? Quantitative MRI assessment for therapy monitoring in rheumatology High resolution qCT for therapy monitoring in rheumatology Abstract to be included
		Room 4	Clinical Science Let's consider Biologic Immunogenicity To obtain the latest information on biologic drug immunogenicity, the practical implications of this information, and the pros and cons of therapeutic drug monitoring for biologic drugs in RA.	13:30:00	Introduction
				13:35:00 13:50:00	Measuring drug levels and anti-drug antibodies - what do the data tell us and what are the practical consequences? Getting to grips with pharmacokinetics of biologic drugs - what is the relevance?
				14:05:00 14:20:00 14:35:00	Therapeutic drug monitoring in RA - aspirations and challenges Therapeutic drug monitoring in RA – what do the data tell us? Debate
		Room 5	Challenges in Clinical Practice Challenges of Planetary changes How much do we have to weight environment in our clinical predictions, both in terms of diagnosis and prognosis? Are we ready to incorporate the environment into our practice? Should we become planetary activists? For each one of the clinical challenges, a reasoned diagnostic prediction and targeted management will be proposed.	13:30:00	Introduction
				13:35:00 13:45:00 14:05:00 14:15:00 14:35:00	Will Simon get RA? Case presentation How much does the environment weight in the prediction? Will Simone get RA? Case presentation Is it obesity or smoking that increases the risk? Q&A
		Room 6	EULAR Debate Patients' input in the target(s) Critically review the Pros and Cons of combining or separating measures of disease process and disease impact in the definition of treat-to-target; Propose the most effective way of incorporating patient perspective into the treatment target(s).	13:30:00	Introduction
				13:35:00 13:45:00 13:55:00	Making the case for replacing PGA Making the case for keeping PGA Q&A and debate

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Friday, 4 June 2021 13:30:00	15:00:00	Room 7	From Bench to Bedside		
			SpA: Innovative techniques in Spondyloarthritis research – Is there light at the end of the tunnel for our patients?		
			To learn about novel techniques in the exploration of the genetic background of spondyloarthritis.	13:30:00	Introduction
			To understand the potency of single cell technology to unravel the underlying pathophysiology of immune-mediated disorders.	13:35:00	Is RNA sequencing the new holy grail?
				14:00:00	Functional genomics in Spondyloarthritis
				14:25:00	How (and when) can Spondyloarthritis patients benefit from basic research breakthroughs?
				14:50:00	Q&A
		Room 8	Practical skills		
			Laboratory course - from the clinic to the lab and back (from translation to prescription)		
			This session will provide an interactive forum for colleagues with interest in the rheumatology lab. State of the art and new lab parameters and detection methods will be discussed for three main sections: arthritides, connective tissue diseases including antiphospholipid syndrome and vasculitides.	13:30:00	ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder
				13:55:00	Vasculitis, systemic autoimmunity
				14:20:00	New trends in biomarkers in inflammatory joint disease
				14:45:00	Q&A
		Room 9	Health Professionals in Rheumatology (HPR)		
			Context matters: Placebo and nocebo effects for pain management		
			Delegates will be able to: describe the importance and mechanisms of placebo and nocebo effect; discuss the role of the context around the treatment in rheumatology; apply concepts of placebo and nocebo and context in their clinical practice.	13:30:00	Introduction
				13:35:00	The individual healing experience
				13:50:00	Q&A
				13:55:00	Mechanisms, predictors, and interventions to prevent, minimize, or extinguish nocebo effects in pain
				14:10:00	Q&A
				14:15:00	Placebo, nocebo and context in clinical practice: How to make use of it
				14:30:00	Q&A
				14:35:00	The power of empathy
				14:50:00	Q&A
14:15:00	15:00:00	Room 1	How to Treat (HOT)		
			HOT Gout		
			Define the treatment objectives in gout;	14:15:00	Introduction
			Explore the treatment options in gout treatment to achieve said objectives;		
			Briefly discuss treatment limitations in selected complex cases (e.g. patients with renal insufficiency or high cardiovascular risk).	14:20:00	HOT Gout
				14:50:00	Q&A
15:30:00	16:15:00	Room 1	What is New (WIN)		
			Osteoarthritis Clinical trials		
			There are many phase II and III clinical trials in OA that have been published in the past 3 years. Several are resolutely negative (anti-cytokine), some are showing disease modifying promise. Session will include an overview of what we have learnt and where new treatments are likely to come from.	15:30:00	Introduction
				15:35:00	WIN in OA clinical trials
				16:05:00	Q&A
	17:00:00	Room 10	EULAR Projects		
			EULAR Projects in musculoskeletal imaging		
			To get updated of the recent projects of ESCMI that have been recently finished	15:30:00	Introduction
				15:35:00	EULAR recommendations for the reporting of musculoskeletal ultrasound studies in rheumatology
				16:00:00	EULAR Recommendations for the use of imaging to guide interventional procedures in patients with RMD
				16:25:00	EULAR-PreS Standardised procedures for Ultrasound Imaging in Paediatric Rheumatology
				16:50:00	Abstract to be included

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Day	Time	Room	Topic	Description	Start	End	Activities	
Friday, 4 June 2021	15:30:00 - 17:00:00	Room 11	PARE What's new: Latest advances in treatment and care in vasculitis and fibromyalgia	To inform about the latest advances in treatment and care in vasculitis and fibromyalgia.	15:30:00	15:40:00	Introduction	
					16:00:00	16:10:00	What's new: Latest advances in treatment and care in vasculitis Discussion	
						16:30:00	16:40:00	What's new: Latest advances in treatment and care in fibromyalgia Discussion
						16:40:00	16:50:00	Abstract to be included Abstract to be included
		Room 12	Practical skills ABCs of biopsies: when to perform and how to interpret	Learn when and how to perform synovial, salivary gland and muscle biopsies; Learn how to interpret synovial, salivary gland and muscle biopsies; Understand the role of synovial, salivary gland and muscle biopsies in the diagnostic pathway.	15:30:00	15:32:00	Introduction	
						15:50:00	Synovial biopsy	
						16:00:00	Discussion	
						16:20:00	Muscle biopsy	
						16:30:00	Discussion	
						16:50:00	Salivary gland biopsy Discussion	
		Room 13	Practical skills Scientific Data Visualisation	To choose the data visualisation that best fits the data. To identify the basics of table and graph design. To choose tables and graphs that tells the story in the data. To learn about poster design.	15:30:00	15:30:00	Workshop: Scientific Data Visualisation	
					Room 2	Clinical Science tsDMARD therapy of rheumatoid arthritis	To understand up to date developments of targeted synthetic oral therapies in rheumatic diseases	15:30:00
	16:00:00				JAKi in the news – side effects			
	16:25:00				"Selective" JAKi on the verge – implications for therapy			
	16:50:00	Ten years of JAKi in RA – Real life data from the SCQM registry Q&A						
Room 3	Clinical Science Controversies on phenotypes in PsA	To describe and discuss the clinical heterogeneity and personalized treatment strategies of psoriatic arthritis. To address the controversies related to the concept and classification of psoriatic arthritis in childhood.	15:30:00	15:35:00	Introduction			
				16:00:00	The clinical heterogeneity of psoriatic arthritis in adults			
				16:25:00	Towards personalized treatment strategies for psoriatic arthritis			
				16:50:00	Controversies around the concept and classification of psoriatic arthritis in children Q&A			
			Room 4	From Bench to Bedside Pharmacology and Microbiota Understand how drug pharmacology and gut microbiota may influence each other; Learn the effect of gut microbiota on drug effectiveness in cancer; Understand how gut microbiota may influence drug therapeutic response in rheumatology.		15:30:00	15:35:00	Introduction
	16:00:00	Drugs and gut microbiome: overview of the bidirectional interactions						
	16:25:00	Gut microbiome and therapeutic response: experiences in the field of cancer						
	16:50:00	Gut microbiome and therapeutic response: applications in rheumatology Abstract to be included						

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Friday, 4 June 2021 15:30:00	17:00:00	Room 5	Challenges in Clinical Practice Managing Chronic Pain Understand the challenges of managing chronic osteoarthritis pain and the opportunities to optimise outcomes using mechanism based treatment strategies; Understand the challenges of managing chronic low back pain and stratified approaches to treatment.	15:30:00 15:45:00 16:05:00 16:15:00 16:35:00	Introduction Case 1: Managing chronic pain in hand osteoarthritis Discussion: Optimising pain management in osteoarthritis: mechanism based treatment strategies Case 2: Managing difficult to treat chronic low back pain Discussion: Stratified targeted treatment strategies for chronic low back pain Q&A
		Room 6	Innovation Artificial Intelligence and Machine Learning in Medicine To understand the potential of artificial intelligence to impact on medicine in the next decade; How to analyse very big data; Understanding complex networks; The advance of robotic surgery.	15:30:00 15:35:00 15:55:00 16:15:00 16:35:00 16:55:00	Introduction Artificial Intelligence in Medicine Translating a trillion points of data into therapeutics Complex networks What can robotic surgery achieve? Q&A
		Room 7	Basic and Translational Science What can we learn from the tissue Participants will learn the importance of pathological tissue analyses in rheumatology and also recognize recent development of analyses.	15:30:00 15:35:00 16:00:00 16:25:00 16:50:00	Introduction What can we learn from the tissues of rheumatic diseases? Single cell analysis of lupus kidney Spatial transcriptomic for tissue analysis Abstract to be included
		Room 8	The Young Rheumatologist How to communicate effectively with the patients To learn how to: communicate effectively with patients with autoimmune rheumatic diseases (RMDs), explain, in newly diagnosed patients, what are RMDs? How are treated and what is expected? Listen to the problems that are important for the patients and identify the unmet needs. Learn how to use all available resources for patients' benefit.	15:30:00 15:35:00 15:45:00 15:55:00 16:05:00 16:15:00	Introduction What do we expect from an appointment with the doctor? The role of HPRs as patients' advocators When I saw a patient with RMD for the first time' What has changed in my clinical practice during the years? Challenges for young rheumatologists when communicating with patients Roundtable discussion
		Room 9	Health Professionals in Rheumatology (HPR) HPR's contribution to the excellence of care in this treat-to-target era: what about personalised goals? Delegates will be able to: discuss the importance of treatment targets from the perspective of the clinician and that of the patient; apply the principles of person-centred care and goal setting in rehabilitation; illustrate in their own practice how both clinical and patient personal goals can be the treatment targets.	15:30:00 15:35:00 15:50:00 15:53:00 16:08:00 16:11:00 16:26:00 16:29:00 16:39:00 16:54:00	Introduction The Dual-target proposal for rheumatic (and other) diseases: Why and how? Q&A How to establish and assess personalized goals? Longstanding experience on using the Goal Attainment Scale and other tools Q&A How to motivate and engage patients in making change Q&A Abstract to be included Wrap-up: Putting it into perspective regarding overall well-being Q&A

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Friday, 4 June 2021	16:15:00	17:00:00	Room 1	<p>How to Treat (HOT) Management of osteoporosis in male patients To learn treatment options and fracture prevention in men osteoporosis, based on current evidence To learn the most updated strategies for the management of men osteoporosis</p>	<p>16:15:00 16:20:00 16:50:00</p>	<p>Introduction Management of osteoporosis in men Q&A</p>
	17:15:00	18:45:00	Room 7	<p>Basic and Translational Science Stress, inflammation & autoimmunity To learn the correlations between stress, inflammation and autoimmunity in RMDs</p>	<p>17:15:00 17:20:00 17:38:00 17:56:00 18:14:00 18:32:00</p>	<p>Introduction Stress, Inflammation, and Autoimmunity: The 3 Modern Erinyes Stress and autoimmune diseases Stress response systems and inflammation The role of stress in subclinical and active RA Abstract to be included</p>
Saturday, 5 June 2021	09:00:00	09:45:00	Room 3	<p>What is New (WIN) Are we what we eat? – The role of dietary intervention in rheumatic and musculoskeletal diseases To learn the current evidence and ways of practical implementation of dietary intervention including fasting in the treatment of RMDs.</p>	<p>09:00:00 09:05:00 09:35:00</p>	<p>Introduction What should I tell about diet to my patients with RMDs? Q&A</p>
	10:30:00		Room 11	<p>PARE Taking control – Managing different expectations towards treatment outcomes To discuss the impact of different expectations in the management of the disease and treatment outcomes. To reflect upon strategies for overcoming poor disease control.</p>	<p>09:00:00 09:05:00 09:10:00 09:15:00 09:20:00 09:25:00 10:05:00 10:25:00</p>	<p>Introduction Assessing treatment failure Adherence and belief Understanding the patient perspective / patient expectation on treatment outcomes Patients' education, expectations and outcomes Discussion Intervention Session summary and closing</p>
			Room 4	<p>Clinical Science Hyperinflammation and Covid19 Understand the mechanisms of hyperinflammation in Covid19 and other contexts; Update current evidence supporting (or not) the use of therapies targeting hyperinflammation in the context of Covid19; Explore the particularities of Covid19-related hyperinflammation in children.</p>	<p>09:00:00 09:05:00 09:25:00 09:45:00 10:05:00 10:15:00 10:25:00</p>	<p>Introduction Mechanisms of hyperinflammation in Covid19 and beyond Success and failures of therapies for hyperinflammation in Covid19 Pediatric inflammatory multisystem syndrome Abstract to be included Abstract to be included Q&A</p>
			Room 5	<p>Challenges in Clinical Practice Is early treatment of RA better than wait and see What is the evidence that early treatment is relevant for disease modification.</p>	<p>09:00:00 09:05:00 09:15:00 09:35:00 09:45:00 10:05:00</p>	<p>Introduction Arthralgia of recent-onset with positive ACPA and synovitis at US: what is the diagnosis and how should we treat this patient? Discussion: Arthralgia of recent-onset with positive ACPA and synovitis at US: what is the diagnosis and how should we treat this patient? How to deal with oligo-arthritis Discussion: How to deal with oligo-arthritis Q&A</p>

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Time	Room	Topic	Start	End	Content
Saturday, 5 June 2021 09:00:00	10:30:00	Room 6 EULAR Debate Remote rheumatology		09:00:00	Debate In a debate the pro's and cons of Remote Rheumatology (accelerated by COVID-19) will be discussed by patients, physicians and health professionals. Pro- and con-statements will be given by those six participants, thereafter a debate will be generated with input from the audience.
		Room 7 Basic and Translational Science Metabolic pathways during the regulation of inflammation and immunity		09:00:00 09:05:00 09:30:00 09:55:00 10:20:00	Introduction Understanding the mutual influence of cellular metabolism and the immune response; Learn about immunometabolic pathways in rheumatic diseases. Krebs Cycle-derived metabolites in the control of inflammation Metabolic basis of sarcoidosis Metabolic rewiring of innate lymphocytes Abstract to be included
		Room 8 Clinical Science Multiple issues in connective tissues - More than 'just' Hypermobility		09:00:00 09:05:00 09:25:00 09:45:00 10:05:00 10:15:00 10:25:00	Introduction To discuss the clinical features of the heritable rheumatological connective tissue disorders using real case studies; To highlight the red flags that should alert the physician to the presence of these conditions and discuss the indications for genetic testing; To discuss common comorbidities; To provide a forum to enable interested audience to increase their clinical skills and consider taking part in future research studies. Joint hypermobility .. Why bother? Beyond chronic pain and fatigue - The role of autonomic dysfunction and psychological concerns in complex cases Vascular Disease in the Heritable Diseases of Connective Tissue Abstract to be included Abstract to be included Q&A
		Room 9 Joint Let's work. Together. To understand the challenges of achieving a fulfilling job if facing an RMD. To know the level of involvement, real and desirable, of all stakeholders in achieving a gratifying work. To explore EULAR and EU initiatives to improve the level of work and the relationship between workers with RMD and their employees.		09:00:00 09:05:00 09:20:00 09:35:00 09:50:00 10:05:00 10:15:00	Introduction The impact of RMD on absenteeism and presenteeism The challenges of achieving a fulfilling job if facing an RMD Can rheumatologists improve the work situation of persons with RMD? How can citizens shape EU policies on employment policies Abstract to be included Abstract to be included
09:45:00	10:30:00	Room 3 How to Treat (HOT) Pregnancy in SLE and APS Discuss recommendations and treatment of pregnancy in SLE and APS		09:45:00 09:50:00 10:20:00	Introduction Common issues in pregnancy management in lupus and anti-phospholipid syndrome Q&A
12:00:00	13:30:00	Room 10 EULAR Projects EULAR Projects in Investigative Rheumatology To provide an overview of the multiomics approaches in 2020 and how to tackle them in Investigative Rheumatology		12:00:00 12:05:00 12:25:00 12:45:00 13:05:00	Introduction Linking single cell RNA seq to RA outcome Data Mining and Modelling for Biomedicine: lessons learned MicroRNA in synovial tissue in arthritis: innocent bystanders? Integrating multiomics data into macrophage biology

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Date	Time	Room	Topic	Start	End	Content	
Saturday, 5 June 2021	12:00:00	13:30:00	Room 11 PARE Members and Volunteers – Unknown beings? How to explore their interests, establish contacts and support To show how to explore the wishes and interests of members and volunteers. To present forms of communicating with volunteers and members. To outline how to interact with and qualify volunteers.	12:00:00	12:00:00	Introduction	
				12:05:00	12:05:00	Volunteers - how to find them, capture them and keep them	
				12:20:00	12:20:00	How a survey to our members changed our work as organisation	
				12:35:00	12:35:00	Qualifying volunteers for their tasks and personal development	
				12:50:00	12:50:00	Abstract to be included	
				13:00:00	13:00:00	Abstract to be included	
				13:10:00	13:10:00	Debate	
				Room 4 Clinical Science Deconditioning in rheumatic disease, time to recognise and tackle it To understand the pathophysiology of deconditioning; To learn about the prevalence of deconditioning in an exemplar rheumatic disease; To learn the therapeutic options to reverse deconditioning.	12:00:00	12:00:00	Introduction
					12:05:00	12:05:00	Deconditioning, lessons from space flight
					12:30:00	12:30:00	How to escape the vicious deconditioning circle
					12:55:00	12:55:00	Deconditioning in juvenile dermatomyositis, a case in point
					13:20:00	13:20:00	Abstract to be included
					Room 5 Challenges in Clinical Practice RA Treatment. Educated choice or educated guess? Case 1: Case presentation of a patient who failed MTX, has bad prognostic factors and needs to decide between the different alternatives of treatment. The case will be followed by discussion on efficacy of the superiority trials. Use or not use of these trials in the decision making; Case 2: Case presentation of a patient who failed TNFi. The case will be followed by discussion on alternatives of treatment on the bases of recent trials. including superiority trials and TNF	12:00:00	12:00:00
				12:05:00		12:05:00	Case 1: Should superiority trials be used to change the guidelines?
				12:15:00		12:15:00	Discussion: Should superiority trials be used to change the guidelines?
				12:35:00		12:35:00	Case 2: Are new trial design favouring the new drugs?
				12:45:00		12:45:00	Discussion: Are new trial design favouring the new drugs?
				13:05:00		13:05:00	Q&A
				Room 6 Innovation Fake News To learn tools and tips for identifying misinformation, trustable sources, and to know examples of misleading statements in rheumatology.	12:00:00	12:00:00	Introduction
					12:05:00	12:05:00	Why do we believe in fake news?
					12:30:00	12:30:00	How do we get deceived?
					12:55:00	12:55:00	Is there misinformation in rheumatology?
					13:20:00	13:20:00	Discussion
					Room 8 The Young Rheumatologist Pearls and Pitfalls of manuscript submission and revision Understand the common errors that may undermine manuscript submission, and discuss with Editors of the main rheumatology journals the various aspects related to the revision process.	12:00:00	12:00:00
12:05:00	12:05:00	Editorial choices: key elements for sending an article to reviewers and the management of conflicting responses					
12:15:00	12:15:00	Rheumatology in clinical medicine journals					
12:25:00	12:25:00	Should we blind reviewers to submitting authors? PROs and CONs (with voting)					
12:35:00	12:35:00	How to avoid rejection for statistical inaccuracy					
12:45:00	12:45:00	Roundtable discussion					

EULAR VIRTUAL CONGRESS 2021

SCIENTIFIC PROGRAMME

Date	Time	Room	Topic	Description	Start	End	Content
Saturday, 5 June 2021	12:00:00	Room 9	Joint, Health Professionals in Rheumatology (HPR)	Delegates will be able to: describe what constitutes self-management in people with inflammatory arthritis; discuss the evidence to support self-management interventions in people with rheumatic inflammatory diseases; identify key communication skills and tools for health professionals to support self-management; describe the skills used by patients to effectively self-manage their health; discuss the role of peer support networks to enhance self-management.	12:00:00		Introduction
			12:05:00				Self-management: it does matter making the effort
			12:20:00				Q&A
			12:23:00				What do healthcare professionals need to support self-management?
			12:38:00				Q&A
			12:41:00				The Power of peers and role of Patient Organizations
			12:56:00				Q&A
			12:59:00				EULAR Recommendations for the implementation of self-management strategies in patients with Inflammatory Arthritis
			13:14:00				Q&A
			13:17:00				Abstract to be included
12:45:00	13:30:00	Room 3	How to Treat (HOT)	Anti-phospholipid syndromes Discuss recommendations and treatment of anti-phospholipid syndrome	12:45:00		Introduction
			12:50:00				Primary and secondary thromboprophylaxis in APS
			13:20:00				Q&A
13:45:00	14:45:00	Room 11	PARE	PARE Highlight Session To provide an overview of learning and outcomes from the 2021 congress from health professionals and the scientific perspectives, and the first feedback from the PARE delegates.	13:45:00		Highlights from the Scientific Programme
							14:15:00
	Room 9	Health Professionals in Rheumatology (HPR)	HPR Highlights session Delegates will be able to: identify important innovation reported in the conference from different perspectives; take home key messages to apply in practice; reinforce new knowledge obtained from the conference for their own professional development.	13:45:00		PARE highlights	
		14:05:00				Highlights from the medical programme	
					14:25:00		HPR highlights